METROPOLITAN LIFE INSURANCE CO/NY - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 111 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
METROPOLITAN LIFE INSURANCE CO/NY ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2024$2,466
-70.7%
1,666
-76.6%
0.00%
Q3 2023$8,408
-16.3%
7,1250.0%0.00%
Q2 2023$10,046
-76.7%
7,125
-59.5%
0.00%
-100.0%
Q4 2021$43,051
-10.5%
17,572
-7.9%
0.00%0.0%
Q3 2021$48,077
-56.4%
19,078
-50.7%
0.00%
-50.0%
Q2 2021$110,32138,7090.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$52,403,2283.69%
Raffles Associates 1,536,946$2,305,4193.14%
Defender Capital, LLC. 5,136,085$7,704,1282.69%
Prescott General Partners LLC 1,851,851$2,777,7770.22%
DAFNA Capital Management LLC 140,000$210,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$67,5000.05%
CTC Capital Management, LLC 14,100$21,1500.04%
Diametric Capital, LP 50,875$76,3130.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$1,172,6490.03%
One68 Global Capital, LLC 13,377$20,0660.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders